ACT News 221.35 06/24/2014 04:23:01 Actavis Inc (ACT)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Actavis Inc (ACT) 221.35 $ACT

Major Indexes Narrowly Lower As Actavis Rallies
at Investor's Business Daily - Mon Jun 23, 12:29PM CDT
Despite better-than-expected economic data, the major averages were still trading flat to slightly lower in early-afternoon trading. The Nasdaq was flat, while the S&P 500 edged down 0.1% and the Dow industrials eased 0.2%. Volume was tracking well...

3 Stocks Driving The Health Care Sector Higher
at The Street - Mon Jun 23, 12:09PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.

Unusual Social Activity Today Around Actavis (ACT)
at The Street - Mon Jun 23, 10:41AM CDT
Trade-Ideas LLC identified Actavis (ACT) as an unusual social activity candidate

Actavis and Forest Laboratories Announce Appointment of C. David Nicholson, PhD to lead Actavis Global Brands Research and Development
Business Wire - Mon Jun 23, 7:30AM CDT
--- Proven Development Track Record in Key Therapeutic Categories including Women's Health, Psychiatric and Cardiovascular -

Settlements, Statements, FDA Submissions and Approvals - Analyst Notes on Valeant, Pfizer, Actavis, Allergan and Teva
PR Newswire - Fri Jun 20, 5:20AM CDT
Today, Analysts Review released its analysts' notes regarding Valeant Pharmaceuticals Intl Inc (NYSE: VRX), Pfizer Inc. (NYSE: PFE), Actavis plc (NYSE: ACT), Allergan, Inc. (NYSE: AGN) and Teva Pharmaceutical Industries Ltd (NYSE: TEVA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3940-100free.

Teva's Nuvigil Patent Infringement Lawsuits Resolved - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 19, 3:45PM CDT
Teva (TEVA) settled its patent infringement lawsuits for Nuvigil with Sandoz, Actavis (ACT), Lupin and Apotex.

Forest Laboratories Nabs Pediatric Exclusivity for Namenda - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 19, 12:20PM CDT
With an additional six months of pediatric exclusivity in the U.S., generic versions of Forest's (FRX) Namenda IR will now enter the market in Jul 2015.

Actavis Confirms District Court Ruling In Generic Exelon® Patch Patent Suit
PR Newswire - Thu Jun 19, 7:30AM CDT
Actavis plc (NYSE: ACT) today confirmed that the United States District Court for the District of Delaware has found certain claims of United States Patent Nos. 6,335,031 and 6,316,023 valid and infringed by Actavis' generic version of Novartis' Exelon® Patch (rivastigmine transdermal system). Actavis is reviewing the court's decision and will evaluate all available options, including an appeal.

Nasdaq, S&P 500 Rally To New Highs After Fed Meeting
at Investor's Business Daily - Wed Jun 18, 3:20PM CDT
The major averages rallied after the Fed said it would keep interest rates near zero and trimmed monthly bond purchases by $10 billion, to $35 billion. The Fed lowered its 2014 economic growth forecast to between 2.1% and 2.3%, from 2.9%, but said...

Stocks Open Mixed In Firm Trade; Adobe, FedEx, Air Products Jump
at Investor's Business Daily - Wed Jun 18, 9:33AM CDT
Stocks churned out a mixed open Wednesday as earnings reports fueled some significant early moves. The Nasdaq slipped 0.2%. The Dow Jones industrial average was down 0.1%. The S&P 500 hung on to a fractional gain. Investor attention on the stock...

Research and Markets: Global IV Iron Drugs Market Report: 2014 Edition
Business Wire - Wed Jun 18, 8:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qdwk3z/global_iv_iron) has announced the addition of the "Global IV Iron Drugs Market Report: 2014 Edition" report to their offering.

Allergan, Actavis Top Big Cap Pharmas Amid M&A Flurry
at Investor's Business Daily - Wed Jun 18, 7:02AM CDT
With 2014 already the strongest year for mergers and acquisitions since 2007, the flurry of dealmaking has given shares of some large drugmakers a shot in the arm -- or face, in the case of Botox maker Allergan (AGN). But not all offers have been...

2014 Report on the International Human Reproductive Technologies Market - Forecast to 2019
M2 - Wed Jun 18, 5:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d66cdt/human) has announced the addition of the "2014 Report on the International Human Reproductive Technologies Market - Forecast to 2019" report to their offering. This report covers the market analysis for various drugs, devices and treatment technologies used in assistance and to control human reproduction. The stakeholders for this study include manufacturers and providers of contraceptive technologies and infertility solutions. The market overview section of the report demonstrates the market dynamics and trends such as the drivers, restraints and opportunities that influence the current nature and future status of this field. Impact factors such as market attractiveness analysis and Porter's five forces analysis have also been explained in the market overview section of the report, in order to give a thorough analysis of the overall competitive scenario in the global human reproductive technologies market. The global human reproductive technologies market is categorized on the basis of various infertility treatments and contraceptive technologies. The infertility technologies market is analyzed in this report with respect to drugs as well as types of treatment procedures. With respect to drugs, the report includes leading brands (by sales) from three major classes, namely, gonadotropins, androgens and erectile dysfunction. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Human Reproduction Technologies Market, by Infertility Treatment Chapter 5 Global Human Reproductive Technologies Market, by Contraceptive Technologies Chapter 6 Global Human Reproductive Technologies Market Revenue, by Geography Chapter 7 Recommendations Chapter 8 Company Profiles Companies Mentioned: - Abbott Laboratories, Inc. - Actavis, Inc. - Bayer AG - Church & Dwight, Co. Inc. - Cook Medical, Inc. - Ferring International Center S.A. - Johnson & Johnson - Merck & Co., Inc. - Merck Serono - Pfizer, Inc. - Reckitt Benckiser Group plc - Teva Pharmaceutical Industries Ltd. - Warner Chilcott plc For more information visit http://www.researchandmarkets.com/research/d66cdt/human

Global IV Iron Drugs Market Report: 2014 Edition
M2 - Wed Jun 18, 5:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/knfh2j/global_iv_iron) has announced the addition of the "Global IV Iron Drugs Market Report: 2014 Edition" report to their offering. The report analyzes the global iron products industry along with an extensive coverage of global and the US IV iron market. The global IV iron market witnesses intense competition with numerous top notch players; such as Galenica Pharmaceuticals, Actavis Inc, AMAG Pharmaceuticals; operating in the marketplace along with small budding players. As a part of analysis of fierce competition prevailing in the industry, product contention has been presented in the report. The company profiles of leading aforementioned players in the market are also incorporated in the report. Some of the major areas of IV iron application include gynecology, gastroenterology, oncology and surgeries. Hemoglobin, Ferritin, Transferrin, and Hepcidin are major molecules which are critical in the function and regulation of iron. The key factors driving growth of the global IV iron industry include escalating number of dialysis and hypertension cases, ameliorating economic conditions, increasing global healthcare expenditures, and rising medicines expenditures. Some of the noteworthy trends and developments of this industry encompass novel product development, bundled payment systems and increasing penetration of genecology sector. However, the growth of this industrial sector is being hindered by stringent regulatory structures and adverse affects associated with the use of IV iron products. Key Topics Covered: 1. Iron in Human Body: An Overview 2. Market Analysis 3. Market Dynamics 4. Competitive Landscape 5. Company Profiles 6. Market Outlook Companies Mentioned - AMAG Pharmaceuticals - Actavis Inc. - Galenica Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/kn...al_iv_iron

Actavis' shareholders approves planned acquisition of Forest for about USD25bn in cash and stock
M2 - Wed Jun 18, 3:52AM CDT
Specialist pharmaceutical company Actavis (NYSE:ACT) stated on Tuesday that all proposals related to its planned acquisition of Forest Laboratories (NYSE:FRX) were approved by their respective shareholders at the recent shareholder meetings.

Actavis and Forest Shareholders Approve Proposals Related to Actavis' Planned Acquisition of Forest
Business Wire - Tue Jun 17, 3:17PM CDT
Actavis plc (NYSE:ACT) and Forest Laboratories, Inc. (NYSE:FRX) today announced that, at shareholder meetings held today, all proposals related to Actavis' planned acquisition of Forest were approved by both Actavis' and Forest's shareholders.

Cardax Appoints Former Novartis, Bristol-Myers Squibb, and Boehringer Ingelheim Executives as Directors
Business Wire - Tue Jun 17, 7:01AM CDT
Cardax, Inc. ("Cardax" (OTCQB:CDXI) announced today the appointment of George W. Bickerstaff, former CFO of Novartis Pharma AG (NYSE:NVS), Tamar D. Howson, former senior business development executive at Bristol-Myers Squibb (NYSE:BMY) and SmithKline Beecham, and Terence A. Kelly, Ph.D., former senior Boehringer Ingelheim anti-inflammatory R&D executive and current CEO of CoMentis, as independent members of its Board of Directors. They will join current Executive Chairman Nicholas Mitsakos, independent director Frank Herringer, and Cardax CEO David G. Watumull on the Cardax Board.

Actavis Strives To Reduce Borrowing Costs
at Investor's Business Daily - Fri Jun 13, 5:48PM CDT
Generic, branded and biosimilar drugmaker Actavis (ACT) may be well-known among investors as a company that has used large acquisitions as one method to boost its earnings and sales sharply. Yet less attention perhaps has been paid to its savvy...
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 270

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 78

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 386

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 518

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 607

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Global Child Tests Purpose Travel's Expanding Media Reach

Updated Category News Views 37

Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 126

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 410

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 445

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 303

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading

Top 5 Most Recently Viewed Articles

XTransfer Partners with Shanghai Pudong Development Bank for Growth

Updated Category News Views 381

Collaboration on Cross-Border Financial Services XTransfer, recognized as a leading global B2B cross-border trade payment platform, is excited to announce its strategic partnership with Shanghai Pudong Development Bank Co. Ltd., Hong Kong Branch. This collaboration aims to enhance cross-border financial services tailored for SMEs engaged in international trade. Focus on...

Continue Reading
SmartOrderLink: Transforming B2B Order Transactions

Updated Category News Views 29

SmartOrderLink's Role in Streamlining B2B Transactions With every new business platform, there's the promise of smoother operations and less headache, and it seems like transcosmos and Kyoei Sangyo's SmartOrderLink might just cut through the chaos of B2B order transactions. Launched in Tokyo, this online order receipt platform promises to smarten up the process,...

Continue Reading
United Bancshares Sees Strong Start with Q1 2025 Results

Updated Category News Views 121

Financial Performance Overview United Bancshares, Inc. (OTCQX: UBOH) has announced significant financial achievements in early 2025, including a quarterly cash dividend declaration that reflects a solid growth trajectory. Quarterly Dividend and Earnings Highlights The Board has declared a cash dividend of $0.23 per share, marking a notable increase of 4.5%. This dividend,...

Continue Reading
Transforming Contact Center Operations: The Pulse Solution

Updated Category News Views 174

Unlock Business Potential with Pulse by OutboundIQ In the competitive matrix of today’s business landscape, effective decision-making is crucial for sustained growth. OutboundIQ has just become a pivotal player in enabling organizations to harness their data more effectively with the launch of Pulse. This innovative tool is designed specifically for contact centers,...

Continue Reading
Growth of Electronic Materials and Chemicals Market Insights

Updated Category News Views 144

Examining the Rapid Growth of the Electronic Materials and Chemicals Market The Electronic Materials and Chemicals Market is projected to reach an impressive USD 110.2 billion, fueled by consistent growth and a forecasted compound annual growth rate (CAGR) of 6.2% from 2024 to 2032. This increase is largely driven by significant advancements in electronic component...

Continue Reading